Aurinia to Present at Cowen and Company 37th Annual Healthcare Conference
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced that its Chief Executive Officer, Richard M. Glickman, will present at the Cowen and Company 37th Annual Healthcare Conference in Boston, MA on March 6, 2017 at 1:20pm ET. A webcast will be available and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.
About Aurinia
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of lupus nephritis (LN), an inflammation of the kidney caused
by Systemic Lupus Erythematosus (SLE) and represents a serious
progression of SLE. The company is headquartered in Victoria, BC and
focuses its development efforts globally. www.auriniapharma.com.
We Seek Safe Harbor.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170302006143/en/
Aurinia Pharmaceuticals Inc.
Investor & Media Contact:
Celia
Economides
Head of IR & Communications
ceconomides@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
Released March 2, 2017
